SciELO - Scientific Electronic Library Online

 
vol.110 número8Adenoma tubular de íleon como causa de sangrado intestinal bajo en lactante menor índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.110 no.8 Madrid ago. 2018

https://dx.doi.org/10.17235/reed.2018.5616/2018 

LETTERS

Anal intraepitelial neoplasia: how and for who do we perform a screening program?

Boris Revollo1  , Sebastià Videla2  3  , David Parés4 

1Servicio de Enfermedades Infecciosas. Hospital Universitari Germans Trias i Pujol. Fundació Lluita Contra la Sida. Badalona, Barcelona, Spain

2Hospital Germans Trias i Pujol. Fundació Lluita Contra la Sida. Badalona, Barcelona, Spain

3Departamento de Farmacología Clínica. Hospital Universitari de Bellvitge. IDIBELL. Universitat de Barcelona. Hospitalet de Llobregat, Barcelona, Spain

4Unidad de Cirurgia Colorrectal. Hospital Germans Trias i Pujol. Fundació Lluita Contra la Sida. Badalona, Barcelona, Spain

Key words: Anal intraepitelial neoplasia; Anal citology; Screening

Dear Editor,

In reference to the interesting article published by Silva et al. 1, we believe it is important to comment on some aspects related to anal cytology as a tool for the screening of anal intraepithelial neoplasia (AIN) in at risk patients.

Our group started an AIN screening program in 2005 2. Since December 2014, a total of 1,916 HIV-infected patients participated in this program 3. During the first ten years of follow-up, the accumulated incidence of invasive anal cancer in the patients who participated in our program was 0.1%, compared to 0.6% in the group of patients who did not want to participate (p = 0.023). Thus, the annual incidence rate was of 20 and 90 per 100,000 person/year, respectively (p = 0.151).

The group of Silva et al. 1 suggests that anal cytology is not the best method as a first screening approach. This opinion goes against our program and that of other groups. Our protocol is based on an initial altered anal cytology (ASCUS, LSIL, HSIL), followed by high-resolution anoscopy (HRA) for diagnosis and treatment with infrared coagulation of high-grade anal dysplasia (AIN II-III) confirmed histologically.

At the moment, we do not have scientific evidence for the best management. We are waiting for the final results of an ongoing clinical trial in order to evaluate if the implementation of an anal cancer screening protocol is justified in at risk patients, which will probably be crucial to establish the best guidelines for daily clinical practice 4. In the meantime, most groups are performing screening programs focused only in men who have sex with men (MSM) with an HIV infection. A HRA and biopsy of suspected AIN is performed in these cases, without a prior anal cytology.

Our group supports an algorithm based on the detection of cases to perform HRA by means of pathology anal cytology. This can have a positive impact on the decline of invasive anal cancer in the participating population. In addition, it is likely to be more efficient from a health economics point of view 3.

We would also like to emphasize that women and probably MSM patients (without HIV infection) should also be considered as at risk and be included in these screening protocols, according to our clinical experience and that of other groups 5.

There is no doubt that the data provided by the ANCHOR trial 4 will probably help us answer many of these questions with more scientific evidence.

Bibliografía

1. Silva M, Peixoto A, Sarmento JA, et al. Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough? Rev Esp Enferm Dig 2018;110(2):109-14. [ Links ]

2. Sirera G, Videla S, Piñol M, et al. Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. AIDS 2013;27(6):951-9. [ Links ]

3. Revollo B, Videla S, Ornela A, et al. Effectiveness of a screening program for anal cancer prevention in HIV-1-infected Patients, 10 years of clinical experience. Boston, MA: CROI; 2018. [ Links ]

4. The ANCHOR study. Disponible en: https://anchorstudy.org/esLinks ]

5. Gaisa M, Ita-Nagy F, Sigel K, et al. High rates of anal high-grade squamous intraepithelial lesions in HIV-infected women who do not meet screening guidelines. Clin Infect Dis 2017;64:289-94. DOI: 10.1093/cid/ciw729 [ Links ]

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons